L-dopachrome tautomerase (Tyrosinase-related protein 2) (DCT)

L-dopachrome tautomerase, also known as Tyrosinase-related protein 2 (TRP-2), is a membrane-bound enzyme located in the melanosomes of melanocytes [UniProt: P40126]. It plays a critical role in the melanin biosynthetic pathway by catalyzing the conversion of L-dopachrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA) [NCBI Gene: 1638]. Beyond its enzymatic function, TRP-2 is highly expressed in most human melanoma cells, making it a significant melanoma-associated antigen (MAA) [PubMed: 10446446]. In the context of oncology, it is a primary target for various immunotherapeutic strategies, including peptide-based vaccines, DNA vaccines like SCIB1, and adoptive T-cell therapies [ClinicalTrials.gov]. These therapies aim to stimulate the immune system to recognize and destroy TRP-2-expressing tumor cells through CD8+ T-cell activation. However, because TRP-2 is also expressed in normal melanocytes, a common side effect of these treatments is vitiligo, characterized by the loss of skin pigment. Research continues to explore TRP-2 as a biomarker for melanoma progression and a focal point for combination therapies involving checkpoint inhibitors.

Other names

TRP-2TRP2TYRP2L-dopachrome Delta-isomeraseMelanoma-associated antigen TRP-2

Induction of antigen-specific cytotoxic T-lymphocyte (CTL) responses against cells expressing the TRP-2 antigen [PubMed: 10446446].